A Large Study of Androgen Receptor Germline Variants and Their Relation to Sex Hormone Levels and Prostate Cancer Risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium
Author(s) -
Sara Lindström,
Jing Ma,
David Altshuler,
Edward L. Giovannucci,
Elio Ríboli,
Demetrius Albanes,
Naomi E. Allen,
Sonja I. Berndt,
Heiner Boeing,
H. Bas Bueno-de-Mesquita,
Stephen J. Chanock,
Alison M. Dunning,
Heather Spencer Feigelson,
J. Michael Gaziano,
Christopher A. Haiman,
Richard B. Hayes,
Brian E. Henderson,
David J. Hunter,
Rudolf Kaaks,
Laurence N. Kolonel,
Loı̈c Le Marchand,
Carmen Martínez,
Kim Overvad,
Afshan Siddiq,
Meir J. Stampfer,
Pär Stattin,
Daniel O. Stram,
Michael J. Thun,
Dimitrios Trichopoulos,
Rosario Tumino,
Jarmo Virtamo,
Stephanie J. Weinstein,
Meredith Yeager,
Peter Kraft,
Matthew L. Freedman
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-1911
Subject(s) - prostate cancer , oncology , androgen receptor , medicine , breast cancer , cohort , germline , cancer , male breast cancer , gynecology , biology , gene , genetics
Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom